Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 19;8(9):e025857.
doi: 10.1136/bmjopen-2018-025857.

'Mind Your Moles' Study: Protocol of a Prospective Cohort Study of Melanocytic Naevi

Affiliations
Free PMC article

'Mind Your Moles' Study: Protocol of a Prospective Cohort Study of Melanocytic Naevi

Uyen Koh et al. BMJ Open. .
Free PMC article

Abstract

Introduction: Having many melanocytic naevi or 'moles' on the skin is the strongest predictor of melanoma; thus, much can be learnt from investigating naevi in the general population. We aim to improve the understanding of the epidemiology and biology of naevi by conducting a 3-year prospective study of melanocytic naevi in adults.

Methods and analysis: This is a population-based cohort study of melanocytic naevi in 200 adults aged 20-69 years recruited via the Australian electoral roll. At baseline, participants will complete a questionnaire on their sun behaviour and health and undergo a clinical examination. Three-dimensional (3D) total-body photography will be used to record the images of skin lesions. Pigmented naevi will be analysed in terms of number, diameter, colour and border irregularity using automated analysis software (excluding scalp, beneath underwear and soles of feet). All naevi ≥5 mm will be recorded using the integrated dermoscopy photographic system. A saliva sample will be obtained at baseline for genomic DNA analysis of pigmentation, naevus and melanoma-associated genes using the Illumina HumanCoreExome platform. The sun behaviour and health follow-up questionnaire, clinical examination and 3D total-body photography will be repeated every 6 months for 3 years. The first 50 participants will also undergo manual counts of naevi ≥2 mm and ≥5 mm at baseline, 6-month and 12-month follow-ups. Microbiopsy and excision of naevi of research interest is planned to commence at the 18-month time point among those who agree to donate samples for detailed histopathological and molecular assessment.

Ethics and dissemination: This study was approved by the Metro South Health Human Research Ethics Committee in April 2016 (approval number: HREC/16/QPAH/125). The findings will be disseminated through peer-reviewed and non-peer-reviewed publications and presentations at conferences.

Keywords: melanocytic naevi; melanoma; moles; skin cancer.

Conflict of interest statement

Competing interests: HPS is shareholder of e-derm consult GmbH and MoleMap by dermatologists. He provides teledermatology reports regularly for both companies. HPS also consults for Canfield Scientific and is an adviser of First Derm.

Figures

Figure 1
Figure 1
Overview of study procedures. 3D, three-dimensional.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11, 2013.
    1. Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. J Invest Dermatol 2016;136:1161–71. 10.1016/j.jid.2016.01.035 - DOI - PubMed
    1. Olsen CM, Neale RE, Green AC, et al. Independent validation of six melanoma risk prediction models. J Invest Dermatol 2015;135:1377–84. 10.1038/jid.2014.533 - DOI - PubMed
    1. Usher-Smith JA, Emery J, Kassianos AP, et al. Risk prediction models for melanoma: a systematic review. Cancer Epidemiol Biomarkers Prev 2014;23:1450–63. 10.1158/1055-9965.EPI-14-0295 - DOI - PubMed
    1. Abbott NC, Pandeya N, Ong N, et al. Changeable naevi in people at high risk for melanoma. Australas J Dermatol 2015;56:14–18. 10.1111/ajd.12181 - DOI - PubMed

Publication types

MeSH terms

Feedback